Cargando…

Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy

BACKGROUND: Surgical resection followed by chemo-radiation postpones glioblastoma (GBM) progression and extends patient survival, but these tumours eventually recur. Multimodal treatment plans combining intraoperative techniques that maximise tumour excision with therapies aiming to remodel the immu...

Descripción completa

Detalles Bibliográficos
Autores principales: Mączyńska, Justyna, Raes, Florian, Da Pieve, Chiara, Turnock, Stephen, Boult, Jessica K. R., Hoebart, Julia, Niedbala, Marcin, Robinson, Simon P., Harrington, Kevin J., Kaspera, Wojciech, Kramer-Marek, Gabriela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8780306/
https://www.ncbi.nlm.nih.gov/pubmed/35057796
http://dx.doi.org/10.1186/s12916-021-02213-z
_version_ 1784637805792591872
author Mączyńska, Justyna
Raes, Florian
Da Pieve, Chiara
Turnock, Stephen
Boult, Jessica K. R.
Hoebart, Julia
Niedbala, Marcin
Robinson, Simon P.
Harrington, Kevin J.
Kaspera, Wojciech
Kramer-Marek, Gabriela
author_facet Mączyńska, Justyna
Raes, Florian
Da Pieve, Chiara
Turnock, Stephen
Boult, Jessica K. R.
Hoebart, Julia
Niedbala, Marcin
Robinson, Simon P.
Harrington, Kevin J.
Kaspera, Wojciech
Kramer-Marek, Gabriela
author_sort Mączyńska, Justyna
collection PubMed
description BACKGROUND: Surgical resection followed by chemo-radiation postpones glioblastoma (GBM) progression and extends patient survival, but these tumours eventually recur. Multimodal treatment plans combining intraoperative techniques that maximise tumour excision with therapies aiming to remodel the immunologically cold GBM microenvironment could improve patients’ outcomes. Herein, we report that targeted photoimmunotherapy (PIT) not only helps to define tumour location and margins but additionally promotes activation of anti-GBM T cell response. METHODS: EGFR-specific affibody molecule (Z(EGFR:03115)) was conjugated to IR700. The response to Z(EGFR:03115)-IR700-PIT was investigated in vitro and in vivo in GBM cell lines and xenograft model. To determine the tumour-specific immune response post-PIT, a syngeneic GBM model was used. RESULTS: In vitro findings confirmed the ability of Z(EGFR:03115)-IR700 to produce reactive oxygen species upon light irradiation. Z(EGFR:03115)-IR700-PIT promoted immunogenic cell death that triggered the release of damage-associated molecular patterns (DAMPs) (calreticulin, ATP, HSP70/90, and HMGB1) into the medium, leading to dendritic cell maturation. In vivo, therapeutic response to light-activated conjugate was observed in brain tumours as early as 1 h post-irradiation. Staining of the brain sections showed reduced cell proliferation, tumour necrosis, and microhaemorrhage within PIT-treated tumours that corroborated MRI T(2)*w acquisitions. Additionally, enhanced immunological response post-PIT resulted in the attraction and activation of T cells in mice bearing murine GBM brain tumours. CONCLUSIONS: Our data underline the potential of Z(EGFR:03115)-IR700 to accurately visualise EGFR-positive brain tumours and to destroy tumour cells post-conjugate irradiation turning an immunosuppressive tumour environment into an immune-vulnerable one. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12916-021-02213-z.
format Online
Article
Text
id pubmed-8780306
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-87803062022-01-21 Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy Mączyńska, Justyna Raes, Florian Da Pieve, Chiara Turnock, Stephen Boult, Jessica K. R. Hoebart, Julia Niedbala, Marcin Robinson, Simon P. Harrington, Kevin J. Kaspera, Wojciech Kramer-Marek, Gabriela BMC Med Research Article BACKGROUND: Surgical resection followed by chemo-radiation postpones glioblastoma (GBM) progression and extends patient survival, but these tumours eventually recur. Multimodal treatment plans combining intraoperative techniques that maximise tumour excision with therapies aiming to remodel the immunologically cold GBM microenvironment could improve patients’ outcomes. Herein, we report that targeted photoimmunotherapy (PIT) not only helps to define tumour location and margins but additionally promotes activation of anti-GBM T cell response. METHODS: EGFR-specific affibody molecule (Z(EGFR:03115)) was conjugated to IR700. The response to Z(EGFR:03115)-IR700-PIT was investigated in vitro and in vivo in GBM cell lines and xenograft model. To determine the tumour-specific immune response post-PIT, a syngeneic GBM model was used. RESULTS: In vitro findings confirmed the ability of Z(EGFR:03115)-IR700 to produce reactive oxygen species upon light irradiation. Z(EGFR:03115)-IR700-PIT promoted immunogenic cell death that triggered the release of damage-associated molecular patterns (DAMPs) (calreticulin, ATP, HSP70/90, and HMGB1) into the medium, leading to dendritic cell maturation. In vivo, therapeutic response to light-activated conjugate was observed in brain tumours as early as 1 h post-irradiation. Staining of the brain sections showed reduced cell proliferation, tumour necrosis, and microhaemorrhage within PIT-treated tumours that corroborated MRI T(2)*w acquisitions. Additionally, enhanced immunological response post-PIT resulted in the attraction and activation of T cells in mice bearing murine GBM brain tumours. CONCLUSIONS: Our data underline the potential of Z(EGFR:03115)-IR700 to accurately visualise EGFR-positive brain tumours and to destroy tumour cells post-conjugate irradiation turning an immunosuppressive tumour environment into an immune-vulnerable one. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12916-021-02213-z. BioMed Central 2022-01-21 /pmc/articles/PMC8780306/ /pubmed/35057796 http://dx.doi.org/10.1186/s12916-021-02213-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Mączyńska, Justyna
Raes, Florian
Da Pieve, Chiara
Turnock, Stephen
Boult, Jessica K. R.
Hoebart, Julia
Niedbala, Marcin
Robinson, Simon P.
Harrington, Kevin J.
Kaspera, Wojciech
Kramer-Marek, Gabriela
Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy
title Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy
title_full Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy
title_fullStr Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy
title_full_unstemmed Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy
title_short Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy
title_sort triggering anti-gbm immune response with egfr-mediated photoimmunotherapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8780306/
https://www.ncbi.nlm.nih.gov/pubmed/35057796
http://dx.doi.org/10.1186/s12916-021-02213-z
work_keys_str_mv AT maczynskajustyna triggeringantigbmimmuneresponsewithegfrmediatedphotoimmunotherapy
AT raesflorian triggeringantigbmimmuneresponsewithegfrmediatedphotoimmunotherapy
AT dapievechiara triggeringantigbmimmuneresponsewithegfrmediatedphotoimmunotherapy
AT turnockstephen triggeringantigbmimmuneresponsewithegfrmediatedphotoimmunotherapy
AT boultjessicakr triggeringantigbmimmuneresponsewithegfrmediatedphotoimmunotherapy
AT hoebartjulia triggeringantigbmimmuneresponsewithegfrmediatedphotoimmunotherapy
AT niedbalamarcin triggeringantigbmimmuneresponsewithegfrmediatedphotoimmunotherapy
AT robinsonsimonp triggeringantigbmimmuneresponsewithegfrmediatedphotoimmunotherapy
AT harringtonkevinj triggeringantigbmimmuneresponsewithegfrmediatedphotoimmunotherapy
AT kasperawojciech triggeringantigbmimmuneresponsewithegfrmediatedphotoimmunotherapy
AT kramermarekgabriela triggeringantigbmimmuneresponsewithegfrmediatedphotoimmunotherapy